Fluorine Substitution Can Block CYP3A4 Metabolism-Dependent Inhibition: Identification of (<i>S</i>)<i>-N</i>-[1-(4-Fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an Orally Bioavailable KCNQ2 Opener Devoid of CYP3A4 Metabolism-Dependent InhibitionYong‐Jin Wu, Michael Sinz, Ronald J. Knox et al.|Journal of Medicinal Chemistry|2003Cited by 59
( <i>S</i> )- <i>N</i> -[1-(3-Morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: An Orally Bioavailable KCNQ2 Opener with Significant Activity in a Cortical Spreading Depression Model of MigraineYong‐Jin Wu, Steven I. Dworetzky, Christopher G. Boissard et al.|Journal of Medicinal Chemistry|2003Cited by 55
Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive DisorderLinda J. Bristow, Michael Sinz, Jyoti Gulia et al.|Journal of Pharmacology and Experimental Therapeutics|2017Cited by 17